BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res 2020;9:S100-19. [PMID: 32206576 DOI: 10.21037/tlcr.2019.11.23] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun S, Frontini F, Qi W, Hariharan A, Ronner M, Wipplinger M, Blanquart C, Rehrauer H, Fonteneau JF, Felley-Bosco E. Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development. Cancer Lett 2021;507:26-38. [PMID: 33713739 DOI: 10.1016/j.canlet.2021.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Grosso S, Marini A, Gyuraszova K, Voorde JV, Sfakianos A, Garland GD, Tenor AR, Mordue R, Chernova T, Morone N, Sereno M, Smith CP, Officer L, Farahmand P, Rooney C, Sumpton D, Das M, Teodósio A, Ficken C, Martin MG, Spriggs RV, Sun XM, Bushell M, Sansom OJ, Murphy D, MacFarlane M, Le Quesne JPC, Willis AE. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat Commun 2021;12:4920. [PMID: 34389715 DOI: 10.1038/s41467-021-25173-7] [Reference Citation Analysis]
3 Schiopu SRI, Käsmann L, Schönermarck U, Fischereder M, Grabmaier U, Manapov F, Rauch J, Orban M. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report. Transl Lung Cancer Res 2021;10:1039-46. [PMID: 33718042 DOI: 10.21037/tlcr-20-1095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lisini D, Lettieri S, Nava S, Accordino G, Frigerio S, Bortolotto C, Lancia A, Filippi AR, Agustoni F, Pandolfi L, Piloni D, Comoli P, Corsico AG, Stella GM. Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach. Int J Mol Sci 2021;22:9014. [PMID: 34445720 DOI: 10.3390/ijms22169014] [Reference Citation Analysis]
5 Sinn K, Mosleh B, Hoda MA. Malignant pleural mesothelioma: recent developments. Curr Opin Oncol 2021;33:80-6. [PMID: 33186182 DOI: 10.1097/CCO.0000000000000697] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Brcic L, Klikovits T, Megyesfalvi Z, Mosleh B, Sinn K, Hritcu R, Laszlo V, Cufer T, Rozman A, Kern I, Mohorcic K, Jakopovic M, Samarzija M, Seiwerth S, Kolek V, Fischer O, Jakubec P, Škarda J, Gieszer B, Hegedus B, Fillinger J, Renyi-Vamos F, Buder A, Bilecz A, Berger W, Grusch M, Hoetzenecker K, Klepetko W, Hoda MA, Filipits M, Dome B. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. Transl Lung Cancer Res 2021;10:1594-607. [PMID: 34012777 DOI: 10.21037/tlcr-20-1114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Fusco N, Vaira V, Righi I, Sajjadi E, Venetis K, Lopez G, Cattaneo M, Castellani M, Rosso L, Nosotti M, Clerici M, Ferrero S. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer 2020;150:53-61. [PMID: 33065463 DOI: 10.1016/j.lungcan.2020.09.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
8 Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C, Giurisato E. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms. Cancers (Basel) 2021;13:5664. [PMID: 34830817 DOI: 10.3390/cancers13225664] [Reference Citation Analysis]
9 Kantor T, Wakeam E. Landmark Trials in the Surgical Management of Mesothelioma. Ann Surg Oncol 2021;28:2037-47. [PMID: 33521898 DOI: 10.1245/s10434-021-09589-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
11 Lopci E, Kobe C, Gnanasegaran G, Adam JA, de Geus-Oei LF. "PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma". Semin Nucl Med 2021;51:458-73. [PMID: 33993985 DOI: 10.1053/j.semnuclmed.2021.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Orbach D, André N, Brecht IB, López Almaraz R, Ben-ami T, Vermersch S, Carton M, Virgone C, Bisogno G, Schneider DT, Bajciova V, Reguerre Y, Galateau-salle F, Stachowicz-stencel T, Dvir R, Rees H, Bien E, Ferrari A, Ben Arush M. Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution. European Journal of Cancer 2020;140:63-70. [DOI: 10.1016/j.ejca.2020.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Costa-Martins S, Vicente I, Valente S. Relapsed malignant pleural mesothelioma: An impressive response to Nivolumab monotherapy. Pulmonology 2021:S2531-0437(21)00197-5. [PMID: 34801435 DOI: 10.1016/j.pulmoe.2021.10.002] [Reference Citation Analysis]
14 Lofiego MF, Cannito S, Fazio C, Piazzini F, Cutaia O, Solmonese L, Marzani F, Chiarucci C, Di Giacomo AM, Calabrò L, Coral S, Maio M, Covre A, On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. Epigenomes 2021;5:27. [PMID: 34968251 DOI: 10.3390/epigenomes5040027] [Reference Citation Analysis]
15 Mansour MSI, Seidal T, Mager U, Dobra K, Brunnström H, Dejmek A. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma. Cancer Cytopathol 2021;129:468-78. [PMID: 33493383 DOI: 10.1002/cncy.22401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Goričar K, Holcar M, Mavec N, Kovač V, Lenassi M, Dolžan V. Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients. J Pers Med 2021;11:1014. [PMID: 34683154 DOI: 10.3390/jpm11101014] [Reference Citation Analysis]
17 Mielgo-Rubio X, Cardeña Gutiérrez A, Sotelo Peña V, Sánchez Becerra MV, González López AM, Rosero A, Trujillo-Reyes JC, Couñago F. Tsunami of immunotherapy reaches mesothelioma. World J Clin Oncol 2022; 13(4): 267-275 [DOI: 10.5306/wjco.v13.i4.267] [Reference Citation Analysis]
18 Anobile DP, Montenovo G, Pecoraro C, Franczak M, Ait Iddouch W, Peters GJ, Riganti C, Giovannetti E. Splicing deregulation, microRNA and Notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2074835] [Reference Citation Analysis]
19 Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM. Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge. Cancers (Basel) 2020;12:E1186. [PMID: 32392897 DOI: 10.3390/cancers12051186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
20 Lanuti M. Commentary: Mesothelioma … moving the needle on locoregional control has invited aggressive treatment options for limited distant metastases. JTCVS Tech 2020;3:363-4. [PMID: 34317932 DOI: 10.1016/j.xjtc.2020.06.032] [Reference Citation Analysis]
21 Reid G, Klebe S, van Zandwijk N, George AM. Asbestos and Zeolites: from A to Z via a Common Ion. Chem Res Toxicol 2021;34:936-51. [PMID: 33749247 DOI: 10.1021/acs.chemrestox.0c00286] [Reference Citation Analysis]
22 Brossel H, Fontaine A, Hoyos C, Jamakhani M, Willems M, Hamaidia M, Willems L. Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma. Cancers (Basel) 2021;13:3211. [PMID: 34199066 DOI: 10.3390/cancers13133211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med 2021;21:148. [PMID: 33952230 DOI: 10.1186/s12890-021-01513-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Yamamoto S, Lee S, Ariyasu T, Endo S, Miyata S, Yasuda A, Harashima A, Ohta T, Kumagai-Τakei N, Ito T, Shimizu Y, Srinivas B, Sada N, Nishimura Y, Otsuki T. Ingredients such as trehalose and hesperidin taken as supplements or foods reverse alterations in human T cells, reducing asbestos exposure-induced antitumor immunity. Int J Oncol 2021;58:2. [PMID: 33655329 DOI: 10.3892/ijo.2021.5182] [Reference Citation Analysis]